Efficacy endpoints for idiopathic pulmonary fibrosis trials

Affiliations

¹ National Institute for Health Research, Southampton Respiratory Biomedical Research Unit, and Clinical and Experimental Sciences, University of Southampton, Southampton SO16 6YD, UK. Electronic address: L.Richeldi@soton.ac.uk.

Comment

Luca Richeldi. Lancet Respir Med. 2015 May.

. 2015 May;3(5):335-7.

doi: 10.1016/S2213-2600(15)00146-0. Epub 2015 Apr 15.

¹ National Institute for Health Research, Southampton Respiratory Biomedical Research Unit, and Clinical and Experimental Sciences, University of Southampton, Southampton SO16 6YD, UK. Electronic address: L.Richeldi@soton.ac.uk.

No abstract available

Comment on

Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.
Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE Jr, Palmer SM, Raghu G, Snyder LD, Anstrom KJ, Martinez FJ; IPFnet investigators. Durheim MT, et al. Lancet Respir Med. 2015 May;3(5):388-96. doi: 10.1016/S2213-2600(15)00093-4. Epub 2015 Apr 15. Lancet Respir Med. 2015. PMID: 25890798 Free PMC article.